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Fine-needle aspiration cytology, which is well established to be accurate for the diagnosis of thyroid cancer, may be inconclusive for
the follicular thyroid neoplasms. As galectin-3 was suggested to be a marker of malignant thyrocytes, we investigated whether this
protein might be helpful in the diagnosis of aspirates classified as undeterminate by cytology. After establishing an easy processing of
aspirates for galectin-3 immunodetection, a series of aspirates categorised as benign (n¼63), malignant (n¼17) or undeterminate
(n¼34) was prospectively analysed for galectin-3. Only the patients with malignant or undeterminate lesions underwent surgery.
Most lesions (86%) diagnosed as malignant by cytology or after surgery were positive for galectin-3. The majority of lesions (94%)
classified as benign by cytology or after surgery was negative for galectin-3. The positive and negative predictive values were 83 and
95%, respectively. When focusing on the undeterminate lesions, the sensitivity and specificity were 75 and 90%, respectively, while
the positive and negative predictive values were 82 and 87%, respectively. The specificity and the positive predictive value were
higher (100%) when considering the percentage of stained cells. Altogether these results show that galectin-3 constitutes a useful
marker in the diagnosis of thyroid lesions classified as undeterminate by conventional cytology.
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Thyroid nodules are very frequent in the population and
their diagnosis by fine-needle aspiration cytology has been
well established to be highly accurate to discriminate malignant
from benign lesions (Dwarakanathan et al, 1989; Baloch
et al, 1998). However, among the various thyroid lesions,
the so-called follicular neoplasms, which include follicular
adenomas and follicular carcinomas, may constitute a diagnostic
problem, as cytological findings may be not sufficient to
assess malignancy. In such cases, many patients are referred to
surgery to perform a histological diagnosis of thyroid nodules and
to look for invasion through the tumour capsule or the blood
vessels. Given that only about 20% of such undeterminate thyroid
lesions will be malignant, a rather high proportion of patients
could have been dispensed from surgery. There is therefore a need
for better identifying thyroid lesions classified as undeterminate by
routine cytology.
Several molecular markers have been investigated in
order to improve the diagnosis of follicular thyroid lesions such
as integrin, E-cadherin, HBME1 (Serini et al, 1996;
Sack et al, 1997). Galectin-3, which is a 31kDa member of
the b-galactoside-binding proteins, seems to be of special
interest. This lectin is both intracellular, where it is located
in the nucleus, cytoplasm and on the cell surface and extracellular
as it can be secreted into the extracellular matrix. Galectin-3
interacts with intracellular glycoproteins such as b-catenin
(Shimura et al, 2004), cell surface molecules (Inohara et al, 1996)
and extracellular matrix proteins (Ochieng et al, 1999). It is
involved in various physiological and pathological processes,
among them cell growth (Inohara et al, 1998), apoptosis (Akahani
et al, 1997), tumour progression and metastasis (Danguy et al,
2002; Takenaka et al, 2004).
One recent study showed for the first time on a large series of
thyroid nodules that galectin-3 as assessed by immunodetection
appeared to be a reliable marker of well-differentiated thyroid
carcinoma with high sensitivity and specificity (Bartolazzi et al,
2001). However, very few data exist focusing on fine-needle
aspiration thyroid samples classified as undeterminate by conven-
tional cytology and the potential help of galectin-3 in better
identifying this subset of lesions. In addition, there are some
technical problems that limit performing routine galectin-3
immunodiagnosis on fine-needle aspiration samples. Indeed,
management of the specimen for galectin-3 immunodiagnosis
needs to be no time-delayed and galectin-3 immunodetection has
been reported most often for cell blocks, that is, paraffin-
embedded cytological samples (Bartolazzi et al, 2001; Saggiorato
et al, 2001) than for fresh smears.
In the present study, the potential interest of galectin-3
in the diagnosis of thyroid nodules categorised as undeterminate
by cytology was evaluated in a prospective series of fine-
needle aspirates. The optimal processing of fine-needle aspira-
tion thyroid samples for subsequent galectin-3 immunodetec-
tion was first defined in order to be realised in routine medical
practice.
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Specimens
Fine-needle aspiration thyroid nodules obtained from 2002 to 2005
were prospectively analysed for galectin-3. Aspiration was realised
with a 26 or 27 gauge needle either under ultrasound control or not
when the nodule was palpable. The obtained material was spread
on slides. For each sample, a sufficient number of slides was
stained with May Gru ¨nwald Giemsa (MGG) for routine cytological
diagnosis, while at least two smears were realised for subsequent
galectin-3 immunocytochemistry.
The prospective analysis concerned the three types of cytological
samples, that is the benign, the malignant and the samples
classified as undeterminate. The term undeterminate meant that
no definitive cytological diagnosis was possible. During the period
of investigation, more than 1500 fine-needle aspirations of thyroid
nodules were performed. As expected, most of these samples were
undoubtedly benign at cytological diagnosis. After having
observed that galectin-3 was always negative in our first series of
benign cases, we then did not systematically analysed all the
benign lesions for galectin-3 but focused on lesions which although
unambiguously benign were highly cellular.
The samples subsequently analysed for galectin-3 (n¼135)
consisted of 63 benign, 17 malignant and 55 undeterminate lesions.
In four cases of malignant lesions, the analysed material was lymph
nodes instead of thyroid tissue as no thyroid nodule was seen by
echography. The cytological diagnosis of these lesions was
unambiguously papillary thyroid carcinoma.
Indication for surgery was based only on clinical and MGG
cytological findings without taking into account the results of
galectin-3 immunodetection. Consequently, only the patients with
lesions diagnosed as malignant or undeterminate by cytology were
supposed to be referred to surgery. Among the 55 patients whose
lesions were classified as undeterminate, 34 underwent surgery
because of the clinical context. The remaining 21 patients were
carefully followed-up or were not operated on by the time we sent
this manuscript. Therefore, analysis of galectin-3 results was
performed for the lesions diagnosed as benign or malignant by
cytology and the subset of undeterminate lesions for which
histological diagnosis was available (n¼114).
The cytological diagnosis of benign lesions was ‘benign follicular
lesions’ based on the presence of unambiguously benign cytolo-
gical findings such as large monolayered sheets of cohesive
follicular epithelial cells and abundant colloid. When the slightest
atypia were found, the samples were diagnosed as undeterminate.
No thyroiditis was included in the present study. The total number
of patients who underwent surgery was 51, including 34 lesions
diagnosed as undeterminate and 17 lesions diagnosed as malignant
by cytology. The histological diagnosis of these lesions is
summarised in Table 1.
Cell culture
The papillary thyroid carcinoma BCPAP cell line (Fabien et al,
1994) was grown in DMEM supplemented with 10% heat-
inactivated foetal calf serum, 100IUml
 1 penicillin, 25mgml
 1
streptomycin and 2mM glutamine. The culture was maintained at
371C in a humidified atmosphere of 5% CO2 and 95% air.
Processing of the aspirates
We determined the optimal processing of fine-needle aspiration
samples for subsequent galectin-3 immunodetection. Specimens
were first tested for transport in CytoLyt (Cytyc, MA, USA).
Samples were aspirated, put in CytoLyt then centrifuged on slide
and tested for galectin-3. Samples were also spread on slides and
analysed for galectin-3 after air-drying only.
To define the optimal time between aspiration of samples and
galectin-3 detection, we tested the human papillary thyroid
carcinoma BCPAP cells. These cells were incubated in CytoLyt
for different times, then centrifuged on slides and tested for
galectin-3. They were also centrifuged on slides without prior
incubation in CytoLyt, dried on air for different times and then
tested for galectin-3.
Galectin-3 immunocytochemistry
Cells on slides were fixed in acetone at 41C for 10min followed by
10% formalin at room temperature for 10min. After blockage of
nonspecific binding sites with 30% normal human AB serum, cells
were incubated overnight at 41C with anti-human galectin-3 NCL-
GAL3 mouse monoclonal antibody (Novocastra, UK) diluted
1:100. Cells were then incubated with EnVision-peroxydase
detection kit as recommended by the manufacturer (Dako,
France). Enzymatic activity was visualised with 3,30-diaminoben-
zidine (Dako). Slides were then washed, counterstained with
haematoxylin and mounted in aqueous medium. For each
experiment, the human papillary thyroid carcinoma BCPAP cell
line was used as positive control. For each sample, a negative
control was realised, which consisted of substitution of the
primary antibody by an isotype-matched mouse nonimmune
IgG1. Positivity for galectin-3 was assessed by two independent
investigators taking into account the percentage of cells exhibiting
staining in the cytoplasm and/or at the plasma membrane. The
positive cases were classifiedþwhen staining was observed in less
than 20% cells, þþfor staining in 20–50% cells and þþþfor
staining in more than 50% cells.
Statistics
Sensitivity, specificity, positive and negative predictive values of
galectin-3 immunodiagnosis were calculated as follows. Sensitivity
Table 1 Histological diagnosis of lesions classified as undeterminate or malignant by cytology
Cytology Histology
Benign (n¼22) Malignant (n¼29)
Follicular adenoma
(n¼14)
Oncocytic
adenoma (n¼8)
Papillary carcinoma
and follicular
variants (n¼25)
Follicular
carcinoma (n¼3)
Medullary
carcinoma (n¼1)
Undeterminate (n¼34)
Follicular lesion (n¼26) 14 9 3
Oncocytic lesion (n¼8) 8
Malignant (n¼17)
Papillary carcinoma (n¼16) 16
Follicular carcinoma (n¼1) 1
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galectin-3 positive to the total number of carcinomas. Specificity
was defined as the ratio of the number of benign lesions, which
were galectin-3 negative to the total number of benign lesions. The
positive predictive value was calculated as the ratio of the number
of galectin-3 positive carcinomas to the total number of galectin-3
positive lesions. The negative predictive value was calculated as the
ratio of the number of galectin-3 negative benign lesions to the
total number of galectin-3 negative lesions.
RESULTS
Optimal processing of the aspirates before galectin-3
immunocytochemistry
We found that detection of galectin-3 was possible for aspirated
samples put in CytoLyt. This transport medium allowed detection
of the protein for samples that have been in CytoLyt as long as
48h. To examine whether the delay between fine-needle aspiration
and galectin-3 immunodetection could be longer than 48h, we
tested the human papillary thyroid carcinoma BCPAP cell line for
galectin-3 after incubation in CytoLyt for different times (4h–7
days). It was clearly shown that galectin-3 labelling decreased with
time to be almost absent after 7 days (Figure 1). Consequently, we
then tested a new protocol where BCPAP cells were not
transported in a medium but only air-dried on slides. We found
that galectin-3 labelling was clearly visible for each time tested and
even as long as 7 days (Figure 2). Therefore, the fine-needle
aspiration samples subsequently analysed were only air-dried
smears, which were tested for galectin-3 within 7 days after
aspiration.
Galectin-3 immunodetection in all aspirates
A series of 114 fine-needle aspirates processed as reported above
and categorised as benign (n¼63), malignant (n¼17) or
undeterminate (n¼34) was prospectively analysed for galectin-3.
Typical examples of galectin-3 labelling using NCL-GAL3 mouse
monoclonal antibody are shown in Figure 3. Detection of galectin-
3 was observed in 30 cases among which three were classified as
benign, 16 as malignant and 11 as undeterminate by cytology. The
percentage of positive cells was variable from 20 to 100%. Galectin-
3 staining was always observed in the cytoplasm. In half cases
(n¼15), cytoplasmic staining was associated with plasma
membrane staining. No nuclear staining was seen.
As it was a prospective study, the patients with lesions classified
as benign due to the presence of undoubtedly benign findings such
as large monolayered sheets of cohesive epithelial cells and
abundant colloid were not operated on. Histological diagnosis
was available only for lesions diagnosed as undeterminate or
malignant by cytology (Table 1). As expected, the histological
4 h
4 days
24 h
7 days
50 m 50 m
50 m 50 m
Figure 1 Galectin-3 immunodetection in CytoLyt-preserved BCPAP cells. The human papillary thyroid carcinoma BCPAP cells were analysed for galectin-
3 after incubation in CytoLyt for different times.
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malignancy. Histology of undeterminate lesions consisted of 22
benign and 12 malignant lesions. Among the 11 indeterminate
lesions positive for galectin-3, nine were diagnosed as malignant
and two as benign by histology. Galectin-3 results according to
histological diagnosis are summarised in Table 2.
4 h 24 h
7 days 4 days
Isotype
50 m 50 m
50 m
50 m
50 m
Figure 2 Galectin-3 immunodetection in air-dried BCPAP cells. BCPAP cells were analysed for galectin-3 after air-drying on slides for different times.
50 m
50 m
200 m
200 m
200 m
200 m
ABC
DEF
Figure 3 Galectin-3 immunodetection in air-dried fine-needle aspiration thyroid samples. Examples of a papillary carcinoma (A–C) and an
undeterminate follicular lesion exhibiting oncocytic metaplasia (D–F), which were positive for galectin-3. Samples were labelled with NCL-GAL 3 mouse
monoclonal antibody (A, B, D, E) or an isotype-matched mouse IgG1 (C, F). (B and E) Higher magnification of (A) and (D), respectively.
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(n¼25, 86%) were positive for galectin-3 (Table 2). Positive cases
were papillary carcinomas (including follicular variants) and one
trabecular carcinoma. In most samples, the staining was observed
in a high percentage of cells, in more than 50% cells in all cases
except two and more than 80% cells in 16 cases. The negative cases
consisted of one follicular variant of papillary carcinoma, two
follicular carcinomas and one medullary carcinoma.
Taking into account all the lesions classified as benign either by
cytology or after surgery (n¼85), the majority of benign lesions
(94%) was negative for galectin-3. Concerning the five positive
lesions, the percentage of labelled cells was less than 50% in all
samples except one.
The sensitivity, specificity, positive and negative predictive
values for galectin-3 in all the aspirates were 86, 94, 83, 95%. When
considering samples to be positive when more than 50% cells were
positive for galectin-3, the specificity as well as the positive
predictive value were higher (99 and 96%, respectively) while the
negative predictive value was similar (93%); however, the
sensitivity was lower (79%).
Galectin-3 immunodetection in undeterminate aspirates
When focusing the analysis of galectin-3 results on undeterminate
lesions, galectin-3 was detected in most malignant lesions and
absent in the majority of benign lesions (Table 3). The sensitivity,
specificity, positive and negative predictive values for galectin-3
calculated for this subset of aspirates are reported in Table 4. If
samples were considered to be positive when labelling was
observed in more than 50% cells, again the specificity and the
positive predictive value were higher (Table 4). The two
undeterminate galectin-3 positive samples, which were diagnosed
as benign, that is one follicular adenoma and one oncocytic
adenoma, exhibited positivity in 30 and 20% cells, respectively.
DISCUSSION
Since the first large series of Bartolazzi et al (2001), several studies
have dealt with the potential usefulness of galectin-3 to better
evaluate thyroid lesions. There has been some controversial results
with studies showing galectin-3 to be a very interesting marker of
malignancy (Orlandi et al, 1998; Saggiorato et al, 2001; Nascimento
et al, 2001; Oestreicher-Kedem et al, 2004), including molecular
profiling studies of follicular thyroid lesions (Finley et al, 2004)
and others reporting that galectin-3 cannot discriminate benign
from malignant thyroid lesions (Mehrotra et al, 2004; Mills et al,
2005). The reasons for this discrepancy might be related to
differences in technical procedures, in the type of thyroid lesions
analysed and to insufficient number of samples tested. In a very
recent review on the optimal management of thyroid nodules
(Castro and Gharib, 2005), galectin-3 was mentioned as an
immunohistochemical marker having shown to be potentially
interesting in preliminary studies. Therefore, there is a need for
other investigations dealing with galectin-3 in thyroid lesions.
Most of the published studies concern retrospective analyses
made on histological specimens or paraffin-embedded cell blocks.
They do not evaluate the interest of galectin-3 as a marker of
malignancy in the subset of lesions for which no diagnosis is
possible by cytology. The present work was a prospective study
and focused on samples classified as underterminate by cytology,
which are the samples of concern.
First of all, we optimised a galectin-3 immunocytochemical
method for fine-needle aspiration thyroid samples. We show here
that galectin-3 immunodetection is possible in routine medical
practice especially as an office procedure. The processing of the
specimens is easy as only air-dried smears are required. This
procedure is shorter and less expensive than imunohistochemistry
performed on paraffin-embedded cell blocks, which is the
technique most often reported for fine-needle aspiration samples
(Bartolazzi et al, 2001; Saggiorato et al, 2001). The delay between
aspiration and galectin-3 immunocytochemistry can be as long as
7 days.
It is important to note that we used a biotin-free detection
system. Indeed, certain thyroid cells, especially oncocytic cells that
are frequently present in follicular adenomas, are known to be rich
in biotin and could be responsible for false-positive results in
biotin-based detection systems (Herrmann et al, 2002).
We always observed galectin-3 labelling in the cytoplasm and
never in the nucleus of follicular cells. Cytoplasmic staining has
been reported to be associated with nuclear staining in some cases
mainly papillary carcinoma (Orlandi et al, 1998; Saggiorato et al,
2001). However, most authors agree that the most significant
localisation of galectin-3 in thyroid lesions is cytoplasm as nuclear
staining can be observed in a high number of benign lesions
namely follicular adenoma (Orlandi et al, 1998; Saggiorato et al,
Table 2 Galectin-3 results according to histological diagnosis of lesions classified as undeterminate or malignant by cytology
Benign (n¼22) Malignant (n¼29)
Follicular adenoma
(n¼14)
Oncocytic
adenoma (n¼8)
Papillary carcinoma
and follicular
variants (n¼25)
Follicular
carcinoma (n¼3)
Medullary
carcinoma (n¼1)
Gal 3-positive 1 1 24 1 0
Table 4 Discrimination between benign and malignant lesions by
galectin-3 for the aspirates diagnosed as undeterminate by cytology
Variable Galectin-3
Galectin-3
(positivity if X50%
stained cells)
Sensitivity (%) 75 67
Specificity (%) 91 100
Positive predictive value (%) 82 100
Negative predictive value (%) 87 85
Table 3 Galectin-3 results for undeterminate lesions according to their
subsequent categorisation as benign or malignant after surgery
Benign (n¼22) Malignant (n¼12)
Gal 3-positive 2 9
Gal 3-negative 20 3
Gal3 staining in X50% cells 0 8
Gal3 staining in o50% cells 22 4
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tumours than thyroid tumours, such as prostate and colon
carcinoma, suggest that galectin-3 plays a dual role according to
its localisation: nuclear galectin-3 would play antitumour functions
while cytoplasmic galectin-3 would promote tumour progression
(Lotz et al, 1993; Honjo et al, 2000; Van den Brule et al, 2000;
Califice et al, 2004).
We also observed staining of galectin-3 at the plasma membrane
in half cases. The localisation of galectin-3 (previously called Mac-
2) at the cell surface has been previously reported (Sato and
Hughes, 1994; Inohara et al, 1996). The finding of plasma
membrane staining is in accordance with the role of galectin-3
in cell–cell and cell–matrix adhesion. For example, galectin-3 is
known to be involved in cell–cell interactions by binding to Mac-2
binding protein (Inohara et al, 1996) and in cell–matrix
interactions by binding to elastin (Ochieng et al, 1999).
Without considering the percentage of stained cells in samples,
calculation of sensitivity, specificity, positive and negative
predictive values for galectin-3 for all the aspirates yielded high
values (490%) for the specificity and the negative predictive
value. When focusing on undeterminate lesions, the specificity and
the negative predictive value were also the highest values and were
almost equal to 90% (Table 4). The fact that these values were
lower for this subset of lesions is probably due to the relatively low
number of cases. However, of interest was the result of the
relatively high negative predictive value of galectin-3 in this subset
of lesions (87%). Indeed, this indicates that the absence of galectin-
3 labelling was associated with the presence of benign lesions in
most cases.
The absence of galectin-3 detection in thyroid carcinomas and
the presence of galectin-3 in benign thyroid lesions have been
previously reported by others (Kovacs et al, 2003), even in the
large study by Bartolazzi, which demonstrated high sensitivity and
specificity (490%) of galectin-3 as a marker of malignant thyroid
lesions (Bartolazzi et al, 2001). In the present study, a relatively
high number of benign lesions were positive for galectin-3, namely
in the subgroup of undeterminate lesions, two out of 22 benign
lesions (9%). In studies dealing with galectin-3 in thyroid lesions
including the largest study of Bartolazzi, positivity for a proportion
of benign lesions has always been reported in cytological as well as
histological samples. The frequency of positivity is around 10%
varying from 4 to 11% (Orlandi et al, 1998; Bartolazzi et al, 2001;
Saggiorato et al, 2001). It has been suggested that some of these
positive cases might constitute cases undergoing malignant
transformation as features suspicious of malignancy such as
hypercellularity, increased nucleus–cytoplasm ratio and mitoses
were observed although no invasion of the capsule or blood vessels
was present (Saggiorato et al, 2001; Coli et al, 2002).
An interesting finding of the present study is that when
galectin-3 labelling was present in benign cases, the percentage
of galectin-3 positive cells was lower than in malignant
cases. When considering samples to be positive if they contained
more than 50% stained cells, the specificity and the positive
predictive value were higher than without considering the
percentage of stained cells (Table 4). No major modification was
found for the sensitivity and the negative predictive value. These
results were found when taking into account all the aspirates as
well as when focusing on undeterminate samples. These findings
suggest that galectin-3 constitutes a better marker of thyroid
malignancy if semiquantitative rather than qualitative results
are taking into account. We propose that the cutoff value to
consider a sample positive or negative for galectin-3 could be 50%
of stained cells.
Considering the malignant cases negative for galectin-3, other
potentially interesting markers such as HBME1 or cytokeratin 19
(Sack et al, 1997; Prasad et al, 2005) should be evaluated. The use
of two or three markers might be more relevant than just one as
recently shown on a series of 37 fine-needle aspiration biopsies
using a panel of markers consisting of galectin-3, HBME1 and RET,
where none of the 20 malignant tumours was negative for this
panel (Rossi et al, 2005).
In conclusion, galectin-3 immunodetection in fine-needle
aspiration thyroid samples is easy and possible in routine medical
practice. This marker is useful in the diagnosis of thyroid lesions
classified as undeterminate by conventional cytology, especially if
semiquantitative results, that is to say the percentage of positive
cells, are taking into account. Galectin-3 allows one to identify the
subset of undeterminate lesions with poor risk of malignancy and
consequently the subgroup of patients who, if in accordance with
the clinics, may be carefully followed-up instead of being referred
to surgery.
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